Loading patent…
AssigneeCytoSorbents Corporation
InventorsPhillip P CHAN, Vincent J. CAPPONI, Thomas D. Golobish, Wei-Tai YOUNG, Ophir ORTIZ, Ritu TRIPATHI
Estimating the term…
The invention concerns methods of treating immunoparalysis by the attenuation via removal of inflammatory mediators and/or checkpoint inhibitor proteins in a subject, comprising treating a subject with a therapeutically effective amount of porous biocompatible polymer sorbent comprising a range of pore diameters between about 50 Å to about 3000 Å and a pore volume between about 0.5 cc/g to about 3.0 cc/g dry polymer; or comprising a range of pore diameters between about 50 Å to about 40,000 Å and a pore volume between about 0.5 cc/g to about 5.0 cc/g dry polymer.
A method of treating immune suppression, anergy, or immunoparalysis by the attenuation via removal of inflammatory, and/or anti-inflammatory mediators, and/or checkpoint inhibitor proteins in a subject, comprising treating a subject with a therapeutically effective amount of porous biocompatible polymer sorbent.
The method of any one of the preceding claims, wherein the sorbent is produced using at least one crosslinking agent and at least one monomer.
A method of reducing sepsis and inflammation related T-cell dysfunction in a subject comprising treating the subject with a therapeutically effective amount of porous biocompatible polymer sorbent.
A method of treating immunoparalysis in a subject in need thereof comprising contacting a physiologic fluid of the subject with a porous biocompatible polymer sorbent, wherein method removes inflammatory mediators, and/or anti-inflammatory mediators, and/or checkpoint proteins.
A method of treating immunoparalysis in a subject in need thereof comprising administering a porous biocompatible polymer sorbent to the subject,
A method of treating immunoparalysis in a subject in need thereof comprising providing to the subject a porous biocompatible polymer sorbent.
A method of treating sepsis and/or inflammation related T-cell or immune cell dysfunction in a subject in need thereof comprising contacting a physiologic fluid of the subject with a porous biocompatible polymer sorbent.
A method of treating sepsis and/or inflammation related T-cell or other immune cell dysfunction in a subject in need thereof comprising administering a porous biocompatible polymer sorbent to the subject,
A method of treating sepsis and/or inflammation related T-cell dysfunction in a subject in need thereof comprising providing to the subject a porous biocompatible polymer sorbent.
Dependencies are inferred from the claim text.